Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMHCNASDAQ:LENZNASDAQ:REPLNASDAQ:VECT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMHCAmplitude Healthcare Acquisition$15.12$11.82$9.80▼$15.80$189M0.11128,744 shs2.25 million shsLENZLENZ Therapeutics$26.87-6.1%$23.57$14.42▼$38.93$740.08M0.43185,226 shs191,481 shsREPLReplimune Group$9.05-0.1%$10.34$4.92▼$17.00$696.99M1.26866,293 shs362,638 shsVECTVectivBio$16.85$16.85$4.25▼$16.98$573.24M0.11N/AN/AThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMHCAmplitude Healthcare Acquisition0.00%0.00%0.00%0.00%0.00%LENZLENZ Therapeutics+6.16%+20.11%+8.25%+16.54%+80.39%REPLReplimune Group+2.37%+13.39%-15.25%-33.33%+43.13%VECTVectivBio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMHCAmplitude Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ALENZLENZ Therapeutics1.9517 of 5 stars3.61.00.00.02.82.50.0REPLReplimune Group3.7674 of 5 stars3.60.00.04.53.61.70.6VECTVectivBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMHCAmplitude Healthcare Acquisition 0.00N/AN/AN/ALENZLENZ Therapeutics 3.17Buy$46.6073.43% UpsideREPLReplimune Group 3.13Buy$19.43114.68% UpsideVECTVectivBio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest AMHC, LENZ, REPL, and VECT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.003/20/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.003/18/2025LENZLENZ TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.002/26/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $18.002/13/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$21.00 ➝ $22.00(Data available from 4/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMHCAmplitude Healthcare AcquisitionN/AN/AN/AN/A$0.40 per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$6.26 per shareN/AVECTVectivBio$27.34M20.97N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMHCAmplitude Healthcare Acquisition-$590KN/A0.00∞N/AN/A66.84%3.31%N/ALENZLENZ Therapeutics-$124.65M-$4.77N/AN/AN/AN/A-58.48%-55.50%5/14/2025 (Estimated)REPLReplimune Group-$215.79M-$3.07N/AN/AN/AN/A-54.84%-42.97%5/15/2025 (Estimated)VECTVectivBio-$93.74MN/A0.00∞N/AN/AN/AN/AN/ALatest AMHC, LENZ, REPL, and VECT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q4 2025REPLReplimune Group-$0.75N/AN/AN/AN/AN/A5/14/2025Q1 2025LENZLENZ Therapeutics-$0.56N/AN/AN/AN/AN/A3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/A2/12/2025Q3 2025REPLReplimune Group-$0.70-$0.79-$0.09-$0.79N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMHCAmplitude Healthcare AcquisitionN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/AVECTVectivBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMHCAmplitude Healthcare AcquisitionN/A1.291.29LENZLENZ TherapeuticsN/A28.6328.63REPLReplimune Group0.1411.4311.43VECTVectivBioN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMHCAmplitude Healthcare Acquisition67.87%LENZLENZ Therapeutics54.32%REPLReplimune Group92.53%VECTVectivBioN/AInsider OwnershipCompanyInsider OwnershipAMHCAmplitude Healthcare AcquisitionN/ALENZLENZ Therapeutics38.40%REPLReplimune Group8.80%VECTVectivBio9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMHCAmplitude Healthcare Acquisition312.50 millionN/ANot OptionableLENZLENZ Therapeutics11027.54 million16.94 millionN/AREPLReplimune Group21077.02 million70.24 millionOptionableVECTVectivBio3034.02 millionN/ANo DataAMHC, LENZ, REPL, and VECT HeadlinesRecent News About These CompaniesIronwood’s shares sink as FDA demands new trial for lead drugApril 15, 2025 | msn.comA brain biotech launches with Roche’s spare partsFebruary 13, 2025 | biopharmadive.comAravax Continues International Expansion with Appointment of Aled Williams as Chief Business OfficerJanuary 21, 2025 | markets.businessinsider.comCDR-Life Appoints Sarah Holland, PhD, as Chief Business OfficerDecember 5, 2024 | finance.yahoo.comRecent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBDNovember 12, 2024 | gut.bmj.comGraft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsightSeptember 23, 2024 | finance.yahoo.comEtherio Group: 2024 CMI 25September 21, 2024 | meetingsnet.comCompare with VectivBio Holding AG (VECT)May 29, 2024 | msn.comenGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of DirectorsMay 15, 2024 | finance.yahoo.comVicore Pharma Holding: Vicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finanznachrichten.deVicore Expands and Strengthens its Board of DirectorsMay 14, 2024 | finance.yahoo.comShort Bowel Syndrome Market by 2032: Forecast Report Estimates Significant GrowthApril 5, 2024 | uk.finance.yahoo.comFDA approves DMD treatment from ItalfarmacoMarch 31, 2024 | cen.acs.orgPipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpointsMarch 18, 2024 | msn.comIronwood Nabs Phase III Win, Still Sees Stock NosediveMarch 1, 2024 | biospace.comIronwood felled by mixed data in short bowel syndrome trialMarch 1, 2024 | pharmaphorum.comUPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage studyMarch 1, 2024 | msn.comIronwood's bowel disease treatment meets main goal in late-stage trialFebruary 29, 2024 | reuters.comWhy Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?February 29, 2024 | benzinga.comOnly two sleeps left until February 31!February 29, 2024 | ft.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialDelta, Walmart Cut Profit Targets: Could Start Domino EffectBy Thomas Hughes | April 10, 2025View Delta, Walmart Cut Profit Targets: Could Start Domino EffectAMHC, LENZ, REPL, and VECT Company DescriptionsAmplitude Healthcare Acquisition NASDAQ:AMHCAmplitude Healthcare Acquisition Corporation does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to focus on the life sciences and pharmaceutical services sectors in the United States and Europe. Amplitude Healthcare Acquisition Corporation was incorporated in 2019 and is based in New York, New York.LENZ Therapeutics NASDAQ:LENZ$26.87 -1.74 (-6.08%) Closing price 04:00 PM EasternExtended Trading$26.92 +0.05 (+0.20%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Replimune Group NASDAQ:REPL$9.05 -0.01 (-0.11%) Closing price 04:00 PM EasternExtended Trading$9.06 +0.00 (+0.06%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.VectivBio NASDAQ:VECT$16.85 0.00 (0.00%) As of 04/24/2025VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy 3 Stocks To Watch For When Tariffs Subside 3 Boring Stocks Outperforming the Market This Year Short Sellers Gave Up on These 3 Names Recently Market Anticipation Builds: Joby Stock Climbs Ahead of Earnings Is Intuitive Surgical a Buy After Volatile Reaction to Earnings? Now Is the Time to Buy ServiceNow—The Rebound Is Real Archer Aviation Gets Analyst Target Upgrade: Time to Load Up? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
